RxDoctor Payments Data

Xiomara Cruz Bracero, MD

Internal Medicine · Mayaguez, PRNPI 1740619956

Payments from drug & device makers

$2,579in general payments, 2019–2025

Across 93 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$227
  • AbbVie$210
  • Lilly USA, LLC$156
  • E.r. Squibb & Sons, L.L.C.$151
  • PBG Puerto Rico LLC$107
  • plus $186 from 5 others

What the payments were for

  • Food & beverage$2,54399%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,579 in reported general payments places this provider in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,463
Medicare patients
19
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol241$250,055
EliquisApixaban226$157,416
TrulicityDulaglutide134$152,908
JardianceEmpagliflozin89$110,723
XareltoRivaroxaban80$73,051
SynthroidLevothyroxine Sodium587$68,167
Xigduo XrDapaglifloz Propaned/Metformin60$49,420
TradjentaLinagliptin34$36,336
SynjardyEmpagliflozin/Metformin Hcl39$30,569
JentaduetoLinagliptin/Metformin Hcl23$25,974
JanumetSitagliptin Phos/Metformin Hcl33$23,662
LantusInsulin Glargine,hum.Rec.Anlog165$20,640
BrilintaTicagrelor36$19,310
OzempicSemaglutide18$17,582
Atorvastatin Calcium1,438$16,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$1,542$276,560288 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Jentadueto, Synjardy Xr$24$238,986227 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Humalog, Humalog Mix 75-25$156$196,942339 claims
Johnson & JohnsonXarelto$227$73,05180 claims
AbbVieSynthroid$210$68,167587 claims
NovartisEntresto$24$15,43913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →